The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Manuel Sarasa
Project Title: The kinetics of the plasma Aβ biomarkers (Aβ42, Aβ40) in the Adult Children Study (ACS).
Date: December 21, 2021 at 5:02 pm
Request ID: T1402
Aim 1: To measure the levels of Aβ plasma markers (DA and RP for Aβ42, Aβ40) in the ACS cohort.
Aim 2: To identify which demographic (age, family history, ApoE genotype, sex, years of education) hematological (hematocrit, blood cell counts, if available in ACS database) and serum biochemical covariables (creatinine, homocysteine, urea, uric acid, hemoglobin, and serum total proteins, if available
Aim 3: Alternatively, these analysis could be performed at Araclon’s lab if a frozen serum sample would be provided) are significantly associated with the levels of Aβ plasma markers in the ACS cohort. Those statistical significant correlates should be included as potential confounding factors in the multi
Aim 4: To describe the progression of plasma Aβ biomarkers over time in each subject and the variation in the trajectories between subjects in a model adjusted for the relevant confounding factors.
Investigator: Mathew Blurton-Jones
Project Title:
Date: December 21, 2021 at 5:02 pm
Request ID: T1404
Aim 1: Generation, gene-correction, and microglial differentiation of iPSC clones from patients with the AD-associated R47H TREM2 mutation.
Aim 2: Do mutations in TREM2 alter the activation state, migration, or phagocytic activity of human microglia?
Aim 3: Do TREM2 mutations alter microglial function and modulate Abeta and tau pathology in vivo?
Aim 4:
Investigator: Ronald DeMattos
Project Title: Analyses of Full-Length, Truncated, and Modified Aβ Species across the Alzheimer’s Disease Spectrum
Date: December 21, 2021 at 5:02 pm
Request ID: T1408
Aim 1: Quantify the multiple forms of deposited Aβ that arise throughout the disease cascade (from normal through moderate stages of disease)
Aim 2:
Aim 3:
Aim 4:
Investigator: Kenneth S. Kosik
Project Title: Gene expression analysis of MAPT mutation carriers
Date: December 21, 2021 at 5:02 pm
Request ID: T1407
Aim 1: Transcriptome sequencing for RNA obtained from neurons derived from iPS patients
Aim 2: Comparison of differentially expressed genes compared to human healthy lines and tissue
Aim 3: miRNA profiling of these samples as in 1
Aim 4: Determination of coexpression modules associated with the MAPT mutations
Investigator: Dr. Tom Montine
Project Title: : Neuropathological assessments of fibrillar amyloid burden in APOE e4 carriers and non-carriers with the clinical diagnosis of Alzheimer’s dementia
Date: December 21, 2021 at 5:02 pm
Request ID: T1406
Aim 1: . In this study, NACC data will be used to compare the proportions of expired brain donors with the clinical diagnosis of Alzheimer’s dementia in terms of their fibrillar amyloid burden and other neuropathologic features
Aim 2:
Aim 3:
Aim 4:
Investigator: Eric J Kremer
Project Title: Screen for a biomarker in early satges of late-onset AD
Date: December 21, 2021 at 5:02 pm
Request ID: T1405
Aim 1: Screen CSF from AD patients for the presence of a cleaved presynaptic protein diminished in early satges of late onset AD
Aim 2: Screen AD SGZ for the presence of a cell adhesion molecule diminished in early satges of late onset AD
Aim 3:
Aim 4:
Investigator: Cruchaga/Sands
Project Title: Identification and functional characterization of the genetic variant causing Kufs’ disease with early dementia in a family with an autosomal dominant inheritance (Amendment)
Date: December 21, 2021 at 5:02 pm
Request ID: T1108-A
Aim 1: to identify the causative variant of Kufs’ disease
Aim 2: to characterize the causative mutations
Aim 3:
Aim 4:
Investigator: Kukull (Penn)
Project Title: Validation of non-amyloid, non-Tau CSF biomarkers of Alzheimer’s disease
Date: December 21, 2021 at 5:02 pm
Request ID: T1403
Aim 1: Aim 1: We will validate 12 non-amyloid, non-Tau CSF biomarkers of AD in samples from subjects with normal cognition, AD, and non-AD dementias, longitudinally followed at the three Centers (WU, Penn, Emory).
Aim 2: Aim 2: We will identify non-amyloid, non-Tau biomarkers suitable as staging and progression biomarkers in AD, evaluate their specificity for AD vs non-AD dementias, and evaluate the technical variability of the relevant assays across three independent Centers.
Aim 3:
Aim 4:
Investigator: RJ Bateman
Project Title: Bioanalytical Assay Method Validation for Alzheimer�s Disease Clinical Trials
Date: December 21, 2021 at 5:02 pm
Request ID: T1418
Aim 1: To create pools of CSF to be used to conduct full bioanalytical method validation on the INNO-BIA AlzBio3 assay for use in clinical trials
Aim 2:
Aim 3:
Aim 4:
Investigator: John A. Kessler
Project Title: Cell autonomous mechanisms of Apolipoprotein E isoform-dependent neurodegeneration
Date: December 21, 2021 at 5:02 pm
Request ID: T1424
Aim 1: Generate isogenic APOE iPSCs from sporadic AD patients and healthy controls.
Aim 2: Evaluate whether calcium dysregulation contributes to increased excitotoxic response in E4- BFCNs.
Aim 3:
Aim 4: